Resero Analytics

What Resero Analytics does

Resero Analytics Inc, founded in 2018 and headquartered in Indianapolis, Indiana, is a private software company building TurboPlatform, a unified scientific-operations platform for nonclinical drug development. The platform is composed of TurboLIMS as the foundational application for protocol design, study execution, animal colony management, and laboratory data capture, supplemented by TurboToxicology for structured toxicology reporting and CTD summaries, TurboPKTK for integrated pharmacokinetic and toxicokinetic analysis, and TurboBioA (in development, planned late 2026) for bioanalytical integration. Architecturally, all applications sit on a shared foundation with a centralized controlled-terminology engine, a single audit-trail system, and a consolidated validation framework, with built-in alignment to 21 CFR Part 11, GLP, SEND 4.0, and a SOC 2 Type 2 readiness roadmap.

The product is positioned against the fragmentation of legacy LIMS systems by collapsing multiple disconnected modules into a single validated environment, with protocol-driven data lineage, role-based access control, and structured SEND package generation integrated into the scientific workflow rather than handled as post-processing. The platform is marketed to large pharmaceutical companies, biotechnology companies, and contract research organizations (CROs), with persona-level users including toxicologists, pathologists, PK scientists, and bioanalytical teams.

Commercially, Resero operates an enterprise field-sales motion with demo-based conversion ('Request a TurboPlatform Demo' and 'Enterprise Discussion' CTAs) and quote-based pricing; the revenue model is subscription/recurring enterprise software licensing. The company is founder-led (CEO David Watson, Ph.D.) with a small team of 1-10 employees, no disclosed institutional funding, no named customers, and no disclosed revenue. Advisory bench strength comes from senior ex-pharma talent, including Andy Dahlem (former VP of R&D at Eli Lilly) and Andrew Vick, Ph.D., supporting enterprise credibility in regulated life-science procurement.

Name

Resero Analytics

Legal name

Resero Analytics Inc

Website

https://reseroanalytics.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Resero Analytics Inc is an Indianapolis-based software company that sells TurboPlatform, a unified protocol-driven platform for nonclinical drug development (LIMS, toxicology, PK/TK, and bioanalytical reporting) to large pharmaceutical, biotech, and CRO customers via enterprise subscriptions.

Ownership category

akta.pro rank

Product category

Nonclinical Drug Development Software

NAICS

Computer Systems Design and Related Services (54151)

SIC

Services-Prepackaged Software (7372)

akta.pro industry

PRIMARYHLAGAJAO

AI/ML Platforms for Drug Discovery & Experiment Optimization

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

SECONDARYHLACAOAO

Biostatistics, Statistical Computing & Clinical Programming (SAS/R/Pipelines)

Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

• Nonclinical study software
• Laboratory information management
• Toxicology reporting software
• Pharmacokinetic analysis platform
• Regulatory submission software

Headquarters

HQ city

Indianapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

1. Software Platform Licensing: Enterprise software licensing model for TurboPlatform applications. Platform includes TurboLIMS, TurboToxicology, TurboPKTK, and TurboBioA (in development). Revenue generated through annual software subscriptions aligned with enterprise deployment and validation framework.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Resero Analytics develops and sells TurboPlatform, a unified scientific-operations software platform for nonclinical drug development. The platform bundles TurboLIMS (protocol design, study execution, laboratory data capture), TurboToxicology (regulatory-ready toxicology reporting and CTD summaries), TurboPKTK (integrated PK/TK analysis), and TurboBioA (in development, late 2026) on a shared architectural foundation with centralized controlled terminology, a single audit-trail system, and a consolidated validation framework supporting GLP, 21 CFR Part 11, and SEND 4.0 compliance.

Product overview

Resero Analytics offers TurboPlatform, a unified platform-plus-modules architecture for the nonclinical study lifecycle. The platform is built around TurboLIMS as the core foundation for study design, execution, and data capture, supplemented by specialized applications: TurboToxicology for toxicology reporting and CTD summaries, TurboPKTK for pharmacokinetic and toxicokinetic analysis, and TurboBioA (in development) for bioanalytical integration. All applications share a common architectural foundation with centralized controlled terminology, unified audit trails, and consolidated validation, enabling data lineage from protocol through regulatory submission.

Differentiator

Problem solved

Functional benefit

Brands

• TurboPlatform: Unified nonclinical study platform composed of integrated applications (TurboLIMS, TurboToxicology, TurboPKTK, TurboBioA) built on a shared architectural foundation.
• TurboLIMS
• TurboToxicology
• TurboPKTK
• TurboBioA

Products and services

• TurboLIMS Foundational nonclinical study platform within the TurboPlatform ecosystem, supporting protocol design, study execution, laboratory data capture, animal colony management, and full data lineage from protocol through animal-level history for downstream analysis and regulatory reporting.
• TurboToxicology Transforms validated study data from TurboLIMS (or any source) into structured, traceable toxicology study reports and regulatory-ready CTD summaries, with integrated clinical pathology, anatomic pathology reporting, and live data updates as studies progress.
• TurboPKTK Delivers integrated pharmacokinetic and toxicokinetic analysis within the TurboPlatform scientific data architecture, using NCA-based workflows with traceable parameter calculations to produce tables, figures, and written outputs for study reports and CTD submissions.
• TurboBioA Integrates bioanalytical analysis and reporting directly into the unified TurboPlatform environment, transforming bioanalytical data from any source into structured analysis supporting method validation, sample analysis, and regulatory submission outputs. Currently in development with general release planned for late 2026.

Quantifiable outcome

• Single validation footprint reduces fragmented requalification effort across multiple disconnected systems
• +2 more outcomes

Segments7 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• LabWare: LabWare is the leading enterprise LIMS provider in pharmaceutical and biotech labs, including regulated nonclinical and GMP environments. It is the most directly comparable competitor to Resero's TurboLIMS, targeting the same large pharma and CRO buyers with a configurable LIMS platform.
• STARLIMS (Abbott Informatics): STARLIMS provides a configurable LIMS platform widely deployed in pharmaceutical, biotech, and public health labs. It is a directly comparable LIMS peer to TurboLIMS, addressing regulated lab data capture, sample tracking, and compliance workflows.
• LabVantage Solutions: LabVantage delivers an enterprise LIMS platform with strong pharmaceutical and life-sciences penetration, including pre-configured solutions for labs and regulated environments. It competes head-to-head with Resero for nonclinical study execution and GLP-compliant data capture workloads.

Emerging players

• Benchling: Benchling is a cloud-native life-sciences R&D platform spanning biology R&D, with growing footprint in regulated workflows. It is a comparable newer-generation platform alternative to Resero, though its center of gravity is biological R&D rather than nonclinical safety/pharmacokinetics.
• Scitara: Scitara provides a lab data integration and connectivity platform for regulated scientific environments, addressing data silo pain points that mirror Resero's legacy-LIMS replacement thesis. It is an emerging player with a more focused lab data exchange layer than Resero's full LIMS scope.

Broad incumbents

• Dotmatics: Dotmatics (now part of Revvity/Siemens partnership context) provides a scientific informatics platform spanning LIMS, ELN, and lab data workflows for pharma and biotech. It is a broader-software peer whose LIMS and lab data offerings overlap with TurboPlatform's regulated nonclinical scope.
• Thermo Fisher Scientific (SampleManager LIMS): Thermo Fisher's SampleManager LIMS is a long-established enterprise platform for regulated labs, sold as part of the broader Thermo Fisher analytical and lab informatics portfolio. It competes with Resero at the Tier-1 pharma LIMS layer with much greater scale and integration breadth.
• Veeva Systems: Veeva is a dominant cloud platform for life sciences spanning CRM, quality, regulatory, and clinical. While it is a much broader player, its regulated life-sciences cloud positioning and penetration into pharma make it a relevant broad incumbent comparable on buyer overlap and cloud architecture approach.
• BIOVIA (Dassault Systèmes): BIOVIA offers a portfolio of life-sciences informatics solutions including LIMS, ELN, and scientific data management, sold into large pharma and biotech. It is a broad incumbent peer with overlapping regulated lab informatics capabilities to Resero's TurboPlatform.

Others

• Arxspan (Bruker): Arxspan, part of Bruker, provides a cloud-based scientific informatics platform including ELN and chemistry data management for pharma R&D. It is thematically adjacent to Resero's regulated scientific data platform strategy though narrower in LIMS scope.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resero Analytics